Posted inPharmaceutical
Bristol Myers Squibb Q3 2026 Results: What the Pipeline Data on CELMoDs and Admilparant Show
The Bristol Myers Squibb Q3 2026 results include CELMoD, admilparant and RYZ101 updates. What each result shows and what is pending.
Posted inBio Technology
Laurus Labs Galenvs Acquisition: The Oligonucleotide and Nanoparticle Technology Behind the Deal
The Laurus Labs Galenvs acquisition buys oligonucleotide and nanoparticle skills. What the technology involves and what is not shown.
Posted inHealthcare Services
Fortis Healthcare Acquisition of Suguna Hospital: What Consolidation Means for Care Quality in Bengaluru
The Fortis Healthcare acquisition adds 110 beds in north-west Bengaluru. What evidence says about hospital deals and quality.
Posted inHealthcare IT
Ro Robin AI Health Agent: What Evidence and Safeguards Should Back a Patient-Facing AI
The Ro Robin AI health agent has launched, but no evidence of benefit was reported. How such tools are tested and which risks matter.
Posted inPharmaceutical
Laurus Labs Q2 Results: The Peptide and Oligonucleotide Capabilities Behind the CDMO Surge
The Laurus Labs Q2 results point to CDMO growth and new peptide capacity. What the science involves and what is not yet shown.
Posted inPharmaceutical
BPaL TB Regimen Patent India: What the Evidence and the Ruling Mean for Drug-Resistant TB
The BPaL TB regimen patent India ruling concerns novelty, not efficacy. How earlier studies figure in the dispute and what is unknown.
Posted inMedical Device
FDA Medline Bed Alert: How Overheating and Entrapment Hazards Arise in Powered Beds
The FDA Medline bed alert reports fire and entrapment hazards. How powered beds can fail and what the sources leave unanswered.
Posted inPharmaceutical
Eli Lilly Q3 2026 Results: The Pipeline and Approvals Behind the Sales Surge
The Eli Lilly Q3 2026 results by pipeline: approvals, oral and weekly options, retatrutide and which medicines remain investigational.
Posted inPharmaceutical
FDA ICH M15 Guidance: How Model-Informed Drug Development Is Evaluated
The FDA ICH M15 guidance frames how models support drug development. What MIDD is, why harmonisation matters and what the webinar covered.
Posted inHealthcare IT
Baby Memorial Hospital DeepInfinity AI Partnership: What Hospital AI Must Prove
The Baby Memorial Hospital DeepInfinity AI partnership plans clinical AI tools. What evidence, safety checks and privacy steps they need.